Page Metadata

Scythian Biosciences

Company Profile

Scythian Biosciences Inc. is a pre-clinical research and development company that is in the process of developing drug therapies. The first project underway is the development of a proprietary cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury. 

In addition to this primary line of research and development, Scythian also intends to develop other potential cannabinoid and non-cannabinoid based pharmaceutical products, including one that is in development for treatment of gastro-inflammatory disease.

Summary

$2.93
$2.95
24,649
$2.47 - $2.93
2,035.90 %
$2.93
$2.47
8,320
--
$81.5M
--
--

Scythian Biosciences

Executive Team
Jonathan Gilbert – CEO, Chairman, and Director
Maghsoud Dariani – Chief Science Officer
Jonathan Held - Chief Financial Officer
David Schrader – Chief Operating Officer
Company IR Website
Nasdaq International, February 22, 2018

Company Details

REGISTERED OFFICE ADDRESS
366 Bay Street, Suite 200, CAN, M5H 4B2
HEAD OFFICE TELEPHONE
GICS INDUSTRY GROUP
Biotechnology

Resources


Social Media


Photo Gallery

Scythian Biosciences Corp

Scythian Logo for Rght Rail
Learn about the company Learn more about Scythian Biosciences' products and services

Scroll up